{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:32:02Z","timestamp":1786609922984,"version":"build-2736575974"},"reference-count":83,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin therapies have significantly advanced obesity management by facilitating clinically significant weight loss and enhancing cardiometabolic outcomes. Nevertheless, their growing application calls for careful consideration of nutritional and behavioural factors, including decreased dietary intake, gastrointestinal symptoms, loss of lean mass, micronutrient deficiencies, and potential weight regain following treatment cessation. Methods: This narrative review synthesises evidence from clinical trials, observational studies, reviews, professional guidelines, and MBS nutrition protocols to evaluate the role of structured dietetic care in adults receiving GLP-1 RAs or related incretin-based therapies for weight management. MBS pathways provide a comparative framework for investigating how established principles of nutritional assessment, monitoring, and dietetic follow-up may inform pharmacological treatments of obesity. Results: The literature indicates that pharmacological weight-loss treatments should not be administered solely as prescription-based treatments. Structured dietetic care can facilitate nutritional assessment, personalised dietary interventions, the management of gastrointestinal symptoms, protein optimisation, behavioural counselling, physical activity support, and long-term weight maintenance. MBS pathways illustrate the role of dietitians in pre-, peri-, and post-major weight-loss interventions through assessment, guidance on supplementation, dietary progression, biochemical monitoring, and long-term maintenance. Although these principles require adaptation rather than direct application to GLP-1 RA pathways, they offer a valuable system for integrating dietitians into comprehensive obesity pharmacotherapy. Conclusions: Structured dietetic care should be regarded as a fundamental component of the pharmacological management of obesity, especially as GLP-1 RAs and incretin-based therapies become more prevalent. Dietitians are well positioned to help optimise nutritional adequacy, preserve lean mass, manage gastrointestinal symptoms, and support sustained weight maintenance. Future research should investigate effective models for delivering dietetic care alongside incretin-based therapies, including strategies to identify patients who need more intensive support.<\/jats:p>","DOI":"10.3390\/nu18162643","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:06:16Z","timestamp":1786608376000},"page":"2643","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do Patients Receiving GLP-1 Receptor Agonists for Weight Loss Require Structured Dietetic Care? Lessons from Metabolic and Bariatric Surgery (MBS) Pathways"],"prefix":"10.3390","volume":"18","author":[{"given":"Vignesh","family":"Balasubaramaniam","sequence":"first","affiliation":[{"name":"Wrexham Maelor Hospital, Wrexham LL13 7TD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Scobie","sequence":"additional","affiliation":[{"name":"Wrexham Maelor Hospital, Wrexham LL13 7TD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-6024","authenticated-orcid":false,"given":"Mary","family":"O\u2019Kane","sequence":"additional","affiliation":[{"name":"Dietetic Department, Leeds Teaching Hospitals NHS Trust, Leeds LS1 9LF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitka","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Surgery, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR4 7TP, UK"},{"name":"Helen McArdle Nursing and Care Research Institute, University of Sunderland, Sunderland SR6 0DD, UK"},{"name":"Faculty of Biomedical Sciences, Austral University, Buenos Aires B1406, Argentina"},{"name":"Faculty of Psychology, University of Anahuac, Mexico City 52786, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Clinical Department of Surgery, Royal Infirmary Edinburgh, University of Edinburgh, Edinburgh EH16 4SA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Mahawar","sequence":"additional","affiliation":[{"name":"Department of Surgery, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR4 7TP, UK"},{"name":"Helen McArdle Nursing and Care Research Institute, University of Sunderland, Sunderland SR6 0DD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1038\/s41598-024-57724-5","article-title":"Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: A systematic review and meta-analysis","volume":"14","author":"Pipek","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"(2026, May 22). Overview|Overweight and Obesity Management|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ng246."},{"key":"ref_7","unstructured":"(2026, May 22). Overview|Semaglutide for Managing Overweight and Obesity|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ta875."},{"key":"ref_8","unstructured":"(2026, May 22). Overview|Tirzepatide for Managing Overweight and Obesity|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ta1026."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sibal, R., Balamurugan, G., Langley, J., Graham, Y., and Mahawar, K. (2025). Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery?. Nutrients, 17.","DOI":"10.3390\/nu17233659"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.obpill.2025.100186","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study","volume":"15","author":"Sulo","year":"2025","journal-title":"Obes. Pillars"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., and Jones, R. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1566498"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults with Overweight or Obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: Systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., and Turri Quarenghi, R. (2025). Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomised Studies. J. Clin. Med., 14.","DOI":"10.3390\/jcm14113791"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomised Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2147\/DMSO.S518912","article-title":"Advances in Perioperative Nutritional Management in Metabolic and Bariatric Surgery","volume":"18","author":"Li","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13087","DOI":"10.1111\/obr.13087","article-title":"British Obesity and Metabolic Surgery Society Guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery-2020 update","volume":"21","author":"Parretti","year":"2020","journal-title":"Obes. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.soard.2019.10.025","article-title":"Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures\u20142019 update: Cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists","volume":"16","author":"Mechanick","year":"2020","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.soard.2016.12.018","article-title":"American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients","volume":"13","author":"Parrott","year":"2017","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00268-021-06394-9","article-title":"Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations: A 2021 Update","volume":"46","author":"Stenberg","year":"2022","journal-title":"World J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1159\/000481825","article-title":"Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management","volume":"10","author":"Busetto","year":"2017","journal-title":"Obes. Facts"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00464-020-07555-y","article-title":"Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: Update 2020, endorsed by IFSO-EC, EASO, and ESPCOP","volume":"34","author":"Antoniou","year":"2020","journal-title":"Surg. Endosc."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Reytor-Gonz\u00e1lez, C., Campuzano-Donoso, M., Sarno, G., Montalvan, M., Horowitz, R., Rossetti, G., Pilone, V., Barrea, L., Muscogiuri, G., and Schiavo, L. (2026). Single vs Dual Agonist Pharmacotherapy for Managing Insufficient Weight Loss and Weight Regain Following Metabolic and Bariatric Surgery: A Comparative Review. Nutrients, 18.","DOI":"10.3390\/nu18040553"},{"key":"ref_28","first-page":"1","article-title":"The value of narrative reviews: Beyond data synthesis","volume":"32","year":"2026","journal-title":"Hum. Reprod. Update"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: A narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes. Pillars"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1111\/dom.70779","article-title":"Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP\/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials","volume":"28","author":"Bressan","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J.J., Mezquita-Raya, P., Carretero-G\u00f3mez, J., Castro, A., Cebri\u00e1n-Cuenca, A., de Torres-S\u00e1nchez, A., Garc\u00eda-de-Lucas, M.D., N\u00fa\u00f1ez, J., Obaya, J.C., and Soler, M.J. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J. Clin. Med., 12.","DOI":"10.3390\/jcm12010145"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100228","DOI":"10.1016\/j.obpill.2025.100228","article-title":"Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1\u2014Based therapies: An expert consensus statement using a modified Delphi approach","volume":"17","author":"Sievenpiper","year":"2025","journal-title":"Obes. Pillars"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Al-Najim, W., Raposo, A., BinMowyna, M.N., and le Roux, C.W. (2025). Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. Nutrients, 17.","DOI":"10.3390\/nu17111934"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100205","DOI":"10.1016\/j.obpill.2025.100205","article-title":"Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions","volume":"16","author":"Fitch","year":"2025","journal-title":"Obes. Pillars"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.clnu.2017.08.016","article-title":"Does nutrition play a role in the prevention and management of sarcopenia?","volume":"37","author":"Robinson","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Assyov, Y., Nedeva, I., Spassov, B., Gerganova, A., Velikov, T., Kamenov, Z., and Velikova, T. (2024). Nutritional Management and Physical Activity in the Treatment of Sarcopenic Obesity: A Review of the Literature. Nutrients, 16.","DOI":"10.3390\/nu16152560"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104486","DOI":"10.1016\/j.cdnut.2024.104486","article-title":"Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications","volume":"8","author":"Grosicki","year":"2024","journal-title":"Curr. Dev. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.celrep.2016.09.047","article-title":"High-Protein Intake during Weight Loss Therapy Eliminates the Weight-Loss-Induced Improvement in Insulin Action in Obese Postmenopausal Women","volume":"17","author":"Smith","year":"2016","journal-title":"Cell Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","first-page":"584175","article-title":"Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1\/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations","volume":"19","author":"Bastemir","year":"2026","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Smits, M.M., and Van Raalte, D.H. (2021). Safety of Semaglutide. Front. Endocrinol., 12, Erratum in Front. Endocrinol. 2021, 12, 786732. https:\/\/doi.org\/10.3389\/fendo.2021.786732.","DOI":"10.3389\/fendo.2021.645563"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.2147\/DMSO.S494919","article-title":"Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist","volume":"17","author":"Gentinetta","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7\u00b72 mg in adults with obesity (STEP UP): A randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr. Nutr. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ka\u0142as, M., St\u0119pniewska, E., Gniedziejko, M., Leszczy\u0144ski-Czeczatka, J., and Siemi\u0144ski, M. (2025). Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14093122"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000548370","article-title":"The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics","volume":"19","author":"Minnetti","year":"2026","journal-title":"Obes. Facts"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement","volume":"15","author":"Donini","year":"2022","journal-title":"Obes. Facts"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000490361","article-title":"Sarcopenic Obesity: Time to Meet the Challenge","volume":"11","author":"Barazzoni","year":"2018","journal-title":"Obes. Facts"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int. J. Eat. Disord."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40519-025-01720-9","article-title":"The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: A systematic review and meta-analysis","volume":"30","author":"Radkhah","year":"2025","journal-title":"Eat Weight Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/ewjm.172.3.164","article-title":"The SCOFF questionnaire: A new screening tool for eating disorders","volume":"172","author":"Morgan","year":"2000","journal-title":"West J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Alexa, R.E., Haliga, R.E., Mor\u0103ra\u0219u, B.C., Ceasovschih, A., S\u00eerbu, O., Asaftei, A., \u0218orodoc, V., and \u0218orodoc, L. (2026). The Nutritional Paradox of Obesity: Mechanisms and Clinical Implications of Micronutrient Deficiencies. Med. Sci., 14.","DOI":"10.3390\/medsci14020160"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e70030","DOI":"10.1111\/cob.70030","article-title":"The Role of the Dietitian in Weight Management of Adults with Obesity Without Diabetes Using Glucagon Like Peptide-1 Agonist Receptors: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials","volume":"15","author":"Moetaz","year":"2025","journal-title":"Clin. Obes."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomised Clinical Trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jand.2024.10.023","article-title":"Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care","volume":"125","author":"Gigliotti","year":"2025","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_62","unstructured":"Academy of Nutrition and Dietetics (2026, May 20). Obesity Medication and the Role of Lifestyle Interventions Delivered by RDNs. Available online: https:\/\/www.eatrightpro.org\/obesity-medication."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e70079","DOI":"10.1111\/obr.70079","article-title":"Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence","volume":"27","author":"Spreckley","year":"2026","journal-title":"Obes. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ojeda-Mercado, D., Fadda, M., Beltrame, B., Tosi, M., Bruno, A., Di Scala, C., Travaglia, G., Vitale, A., Schiano di Cola, R., and Boschetti, S. (2026). The Role of the Dietitian in Incretin-Based Obesity Therapies in Italy: Practical Clinical Challenges, Professional Clarity, and the Sarcopenic Obesity Perspective. Dietetics, 5.","DOI":"10.3390\/dietetics5010017"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jand.2022.11.014","article-title":"Medical Nutrition Therapy Interventions Provided by Dietitians for Adult Overweight and Obesity Management: An Academy of Nutrition and Dietetics Evidence-Based Practice Guideline","volume":"123","author":"Raynor","year":"2023","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jand.2024.06.222","article-title":"Medical Nutrition Therapy: Still Relevant in the Era of Pharmacotherapy for Obesity Care","volume":"125","author":"Miller","year":"2025","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_67","unstructured":"(2026, July 03). New Joint Statement Regarding GLP-1\/GIP Receptor Agonists for People Living with Obesity and\/or Type 2 Diabetes Released\u2014BDA. Available online: https:\/\/www.bda.uk.com\/resource\/new-joint-statement-regarding-glp-1-gip-receptor-agonists-for-people-living-with-obesity-and-or-type-2-diabetes-released.html."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100143","DOI":"10.1016\/j.obpill.2024.100143","article-title":"Optimising nutrition, diet, and lifestyle communication in GLP-1 medication therapy for weight management: A qualitative research study with registered dietitians","volume":"12","author":"Despain","year":"2024","journal-title":"Obes. Pillars."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e13296","DOI":"10.1111\/obr.13296","article-title":"Effect of exercise training before and after bariatric surgery: A systematic review and meta-analysis","volume":"22","author":"Bellicha","year":"2021","journal-title":"Obes. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2213-8587(26)00122-1","article-title":"Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement","volume":"14","author":"Dobbie","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s13668-024-00548-6","article-title":"Nutritional considerations during major weight loss therapy: Focus on optimal protein and a low-carbohydrate dietary pattern","volume":"13","author":"Volek","year":"2024","journal-title":"Curr. Nutr. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.advnut.2023.07.008","article-title":"Food and nutrition insecurity in Europe: Challenges and opportunities for dietitians","volume":"14","year":"2023","journal-title":"Adv. Nutr."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"wjaf011","DOI":"10.1093\/obendo\/wjaf011","article-title":"Semaglutide in a real-world outpatient setting: Discontinuation patterns and weight maintenance","volume":"1","author":"Brufani","year":"2025","journal-title":"Obes. Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amepre.2013.08.019","article-title":"Weight-loss maintenance for 10 years in the National Weight Control Registry","volume":"46","author":"Thomas","year":"2014","journal-title":"Am. J. Prev. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E1413","DOI":"10.1503\/cmaj.240768","article-title":"Glucagon-like peptide-1 receptor agonists during pregnancy and lactation","volume":"196","author":"Zipursky","year":"2024","journal-title":"CMAJ"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Muller, D.R.P., Stenvers, D.J., Malekzadeh, A., Holleman, F., Painter, R.C., and Siegelaar, S.E. (2023). Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: A systematic review of the evidence. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1215356"},{"key":"ref_79","unstructured":"(2026, July 10). Wegovy 7.2 mg Solution for Injection in Pre-Filled Pen\u2014Patient Information Leaflet (PIL)\u2014(emc)|102093. Available online: https:\/\/www.medicines.org.uk\/emc\/product\/102093\/pil."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1093\/jn\/nxac164","article-title":"Food Intake Following Gastric Bypass Surgery: Patients Eat Less but Do Not Eat Differently","volume":"152","author":"Livingstone","year":"2022","journal-title":"J. Nutr."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/oby.22272","article-title":"Bariatric Surgery Does Not Affect Food Preferences, but Individual Changes in Food Preferences May Predict Weight Loss","volume":"26","author":"Rasmussen","year":"2018","journal-title":"Obesity"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/cob.12066","article-title":"Evaluation of a multidisciplinary Tier 3 weight management service for adults with morbid obesity, or obesity and comorbidities, based in primary care","volume":"4","author":"Jennings","year":"2014","journal-title":"Clin. Obes."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00125-020-05224-2","article-title":"Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)\/Counterweight-Plus weight management programme","volume":"63","author":"Xin","year":"2020","journal-title":"Diabetologia"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/16\/2643\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:25:39Z","timestamp":1786609539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/18\/16\/2643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":83,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["nu18162643"],"URL":"https:\/\/doi.org\/10.3390\/nu18162643","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}